World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

Marianne De Backer net worth and biography

Marianne De Backer Biography and Net Worth

Director of Arrowhead Pharmaceuticals

Marianne De Backer is currently Executive Vice President, Head of Global Business Development & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of Bayer AG. Before joining Bayer, Dr. De Backer held a series of positions in the Johnson & Johnson family of companies. She started as a scientist and scientific group leader during which time her work resulted in multiple patents. She progressed through commercial positions internationally including leading a sales and marketing business unit responsible for several product lines, culminating as Vice President, M&A Operations, Divestitures, and Janssen Business Development. During her tenure with Johnson & Johnson, Dr. De Backer had direct accountability for over 200 strategic alliances. Dr. De Backer received a MSc in Molecular Biology from the University of Brussels, Belgium, a Masters in Engineering and Biochemistry and a Ph.D. in Biotechnology from the University of Ghent, Belgium, and an MBA from Rotterdam School of Management, Erasmus University, The Netherlands.

What is Marianne De Backer's net worth?: The estimated net worth of Marianne De Backer is at least $14.61 million as of April 3rd, 2024. De Backer owns 678,457 shares of Arrowhead Pharmaceuticals stock worth more than $14,613,964 as of April 25th. This net worth estimate does not reflect any other assets that De Backer may own. Learn More about Marianne De Backer's net worth.
How do I contact Marianne De Backer?: The corporate mailing address for De Backer and other Arrowhead Pharmaceuticals executives is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. Arrowhead Pharmaceuticals can also be reached via phone at (626) 304-3400 and via email at [email protected]. Learn More on Marianne De Backer's contact information.
Has Marianne De Backer been buying or selling shares of Arrowhead Pharmaceuticals?: Marianne De Backer has not been actively trading shares of Arrowhead Pharmaceuticals within the last three months. Most recently, Backer Marianne De sold 5,000 shares of the business's stock in a transaction on Thursday, June 24th. The shares were sold at an average price of $89.85, for a transaction totalling $449,250.00. Learn More on Marianne De Backer's trading history.
Who are Arrowhead Pharmaceuticals' active insiders?: Arrowhead Pharmaceuticals' insider roster includes Christopher Anzalone (CEO), Marianne De Backer (Director), Mauro Ferrari (Director), Douglass Given (Director), James Hamilton (Sr. VP of Discovery & Translational Medicine), James Hassard (Insider), Kenneth Myszkowski (CFO), Patrick O'Brien (General Counsel), Tracie Oliver (Insider), Adeoye Olukotun (Director), Javier San Martin (Insider), and William Waddill (Director). Learn More on Arrowhead Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Arrowhead Pharmaceuticals?: In the last year, Arrowhead Pharmaceuticals insiders bought shares 2 times. They purchased a total of 2,000 shares worth more than $54,990.00. In the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 408,135 shares worth more than $13,514,007.79. The most recent insider tranaction occured on March, 20th when Director Hongbo Lu bought 1,000 shares worth more than $27,500.00. Insiders at Arrowhead Pharmaceuticals own 4.5% of the company. Learn More about insider trades at Arrowhead Pharmaceuticals.
Information on this page was last updated on 3/20/2024.

Marianne De Backer Insider Trading History at Arrowhead Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/24/2021	Sell	5,000	$89.85	$449,250.00
6/15/2020	Buy	500	$31.33	$15,665.00	13,000
3/16/2020	Buy	500	$23.94	$11,970.00	13,000
3/11/2020	Buy	500	$28.60	$14,300.00	13,000
2/27/2020	Buy	500	$35.07	$17,535.00	13,000
1/13/2020	Buy	500	$54.95	$27,475.00	13,000

Marianne De Backer Buying and Selling Activity at Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Company Overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Today's Range

Now: $21.54

$21.49

$22.90

50 Day Range

MA: $28.28

$22.33

$36.08

2 Week Range

Now: $21.54

$20.67

$42.48

Volume

335,100 shs

Average Volume

1,449,872 shs

Market Capitalization

$2.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad